巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    PharmaCyte Biotech

    PMCB
    2.220
    0.050
    2.20%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・PharmaCyte Biotech - 延遲價格・最後更新於 20/05 12:15
    最高位
    2.250
    最低位
    2.180
    開市價
    --
    前收市價
    2.270
    成交量(千)
    1.34
    成交額(百萬)
    0.03
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    46.00
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    16.900 - 0.007
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    PharmaCyte Biotech
    證券代碼
    PMCB.US
    所屬板塊
    Biotechnology
    公司業務
    PharmaCyte Biotech Inc is a clinical stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed. It is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer killing drugs at the source of cancer.
    發行量
    5141083
    公司總部
    23046 Avenida de la Carlota, Suite 600
    公司網址
    https://www.pharmacyte.com
    公司電郵
    info@PharmaCyteBiotech.com
    公司電話
    +1 917 595-2850
    暫無內容

    關於

    PharmaCyte Biotech(PMCB.US)所屬的行業板塊為Biotechnology。
    PharmaCyte Biotech Inc is a clinical stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed. It is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer killing drugs at the source of cancer.
    詳細公司背景可參考: https://www.pharmacyte.com